Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HSG4112 High-Dose Safety and PK in Healthy Subjects
NCT05310032Phase 1Completed
- Sponsor
- Glaceum
- Start
- Apr 2022
- Primary completion
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of vutiglabridin in obesity (5 arms), sponsored by Glaceum. Primary endpoints: Maximum Plasma Concentration, Maximum Plasma Concentration at Steady State and 13 more. Started Apr 2022; status: completed.
02
Drugs
vutiglabridin
03
Conditions
obesity
Beyond the preview
Go deeper on NCT05310032.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05310032.